Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-EGFR CAR T Cells for EGFR-Overexpressing Malignant Glioma
NCT02331693Phase 1Unknown
- Sponsor
- Renji Hospital
- Start
- Dec 2014
- Primary completion
- Dec 2015
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in glioblastoma (GBM) and Gliosarcoma (GS), sponsored by Renji Hospital. Primary endpoint: Adverse events attributed to the administration of the anti-EGFR CAR T cells at 2 years. Status: unknown.
02
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT02331693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02331693.